GE HealthCare's Tax Rate Fell To 17.1% From 27.8%, Widening Its Earnings-Per-Share Gain
Third-quarter net income rose to $615 million while the adjusted per-share gain was smaller than the reported one.
GE HealthCare, which makes medical imaging equipment, patient monitors and diagnostic imaging agents, cut its third-quarter effective tax rate to 17.1% from 27.8% a year earlier, according to its 10-Q. That helped lift net income attributable to the company to $615 million from $446 million, and reported earnings per share outgrew the adjusted figure.
Reported and adjusted EPS diverge
Diluted earnings per share rose to $1.36 from $0.98. Adjusted EPS, which strips out tax items and other adjustments, rose to $1.34 from $1.07, so the standard-accounting gain outpaced the adjusted one, per the earnings release.
Pre-tax income was $752 million against $643 million. The provision for income taxes fell to $129 million from $179 million, a $50 million drop the company attributed mainly to foreign income tax reserve releases and changes in reconciling adjustments to recorded tax account balances, partly offset by a foreign tax audit settlement.
The adjusted reconciliation carries Spin-Off and other tax adjustments of negative $37 million this quarter, against positive $39 million a year ago. The adjusted effective tax rate was 22.0%, against 21.8%.
Operations also improved
Revenue rose 7.2% to $5.5 billion, or 6.2% organically. Operating income climbed to $805 million from $653 million, helped by volume, pricing and lower tariff expense. Direct tariffs cut operating income by $53 million in the quarter, against $95 million a year earlier.
The company also received $55 million of tariff refunds in the quarter after the Supreme Court ruled in February that the emergency-powers law did not authorize the tariffs. The company raised its full-year guidance.
Buybacks paused, SOFIE deal ahead
The company repurchased no shares in the third quarter. Over nine months it bought 4.7 million shares for about $300 million, and $500 million remains on its authorization.
It announced on October 5 an agreement to buy SOFIE Biosciences, a maker of PET radiopharmaceuticals on contract, for $945 million in cash. Closing is expected in the first half of 2027, subject to regulatory approvals.
In the 8-K, the company also said Jeannette Bankes will resign as head of Patient Care Solutions, with her last day November 15; Neal Sandy takes over November 16, per the release.
The SOFIE purchase is targeted to close in the first half of 2027.
Sources
- 10-Q Filing — GE HealthCare Technologies (GEHC) — SEC EDGAR
- 10-Q Filing — GE HealthCare Technologies (GEHC), Q2 FY2026 filed 2026-07-29 (comparison basis) — SEC EDGAR
- 8-K Filing — GE HealthCare Technologies, filed 2026-10-28 (Items 2.02, 5.02, 9.01) — SEC EDGAR
- Earnings release (8-K Item 2.02, release3q26earnings.htm) — GE HealthCare Technologies, filed 2026-10-28 — SEC EDGAR
- GEHC Ahead of Q3 Earnings: Can Strong Demand Offset Macro Headwinds? — Yahoo Finance
- GE HealthCare reports third quarter 2026 financial results – Company Announcement - FT.com — Financial Times
- GE HealthCare Technologies Q3 2026 Earnings Preview (GEHC:NASDAQ) — seekingalpha.com
- GE HealthCare Technologies Non-GAAP EPS of $1.34 beats by $0.14, revenue of $5.51B beats b — seekingalpha.com